Despite the effective frontline treatment of classical Hodgkin lymphoma (cHL), about 10% of early-stage and 30% of advanced stage patients experience disease relapse or have refractory disease [1] . Only half of relapsed/refractory (R/R) patients can be cured with salvage chemotherapy followed by high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) [2] . For patients relapsing after second-line treatment, the possible effective therapy 
Introduction
Patients received nivolumab intravenously over 60 minutes at 3 mg/ kg every 2 weeks until disease progression or unacceptable toxicity.
Efficacy data including overall response rate (ORR), complete remission (CR) rate, progression-free survival (PFS) and overall survival (OS) as well as the safety data were collected. Computed tomography (CT) scans of neck, chest, abdomen and pelvis were obtained before therapy, 3 months after starting treatment and repeated every 6 months. 18F-fluorocholine deoxyglucose positron emission tomography (PET) combined with computed tomography (PET-CT) was performed before nivolumab treatment and for confirmation of suspected progressive disease (PD). Response evaluation was performed according to 2014 Lugano classification [16] . Eligible patients with objective response to treatment were considered for consolidation with either HDT/ASCT or allo-SCT according to the local policy. For patients who discontinued nivolumab to proceed to transplantation, disease assessment (CR, non-CR) was performed according to local standards and clinical symptoms. The data on the transplantation and graft-versus-host-disease (GVHD) were collected. HDT platinum-based and ifosfamide-containing regimens [17] [18] [19] [20] [21] [22] and myeloablative conditioning were administered according to standard criteria [23] . Supportive treatment was administered as required according to the local standards, including adequate fluid intake and allopurinol for tumor lysis syndrome prevention. Safety outcomes were the incidence of adverse events (AEs), classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 [24] .
To characterize the study group and response to therapy we used descriptive statistical methods. Survival analysis was performed by Kaplan-Meier method; both PFS and OS were calculated from the time Nivolumab therapy was initiated to time of progression, death from any cause or the date of the last follow-up. Statistical analyses were performed using the software Statistica, version 10 (StatSoft, Krakow, Poland). Stage, n (%)
Results

Between
B symptoms, n (%) 13 (81) Bulky disease, n (%) 11 (69) Extranodal involvement, n (%) 44 (7) Median IPI, number (range) 4 (2-6)
Disease status
Primary refractory, n (%) 6 (37)
Relapsed, n (%) 10 (62)
ASCT before nivolumab, n (%) 44 (7) ASCT Acute graft versus host disease (aGVHD) was not reported.
Cutaneous chronic graft versus host disease (cGVHD) was noted in 2 patients. After allo-SCT 2 patients died; the first one because of thrombotic thrombocytopenic purpura (TTP), the second one due to massive mycosis and fungal pneumonia. We did not observe disease progressions after allo-SCT.
Discussion
Outcomes for patients with cHL have improved significantly over the last decades thanks to the effective frontline chemotherapy such as ABVD or escBEACOPP [25] . However, R/R cases, both in the pretransplant setting and relapsing after ASCT, have a high priority to the use of novel agents, not only short-term effective, but also overcoming disease resistance. In the pivotal phase II study, BV has shown significant clinical efficacy in R/R cHL patients after ASCT with ORR of a75%, CR of 34% and a median PFS of 9.3 months [7, 26] . Patients who are refractory or relapse after BV therapy are a challenge. PD-1 blocking antibodies now represent a major breakthrough in the treatment of R/R cHL after ASCT and BV. After the encouraging data from extended analysis of three CheckMate 205 cohorts [27] , confirming the efficacy and favorable safety profile Our real-life experience with nivolumab in R/R cHL patients who failed after BV therapy, showed a higher response rate (81%) and CR rate (56%) comparing to similar population of patients from cohort C of Checkmate205 study (patients after BV and/or ASCT, with 69%
ORR and 12% CR) [27] . CR rates were assessed by CT scans, we did not perform PET assessment to confirm CR, because the immune reactions within tumours that may have contributed to persistence of fluorodeoxyglucose (FDG) uptake and thereby understate the CR rate [12] . We understand that in real-life the confirmation of CR was carried out by investigators, not the independent reviewers, however the results are encouraging, though needing further observation and evaluation. Furthermore, it is worth noting, that the high percentage of responders was obtained in patients refractory to BV (67%). It may be related to the mechanism of PD-1 blockade, completely different from the mechanism of cytostatics and ADC such as BV.
The role of allo-SCT consolidation after anti-PD-1 treatment is still unclear because of the higher risk of GVHD [11, 12] . On the other hand, there are limited therapeutic options available in the case of disease relapse. At this time it is difficult to make any conclusions regarding the use of nivolumab as a bridge to allo-SCT, but certainly transplantation continues to be a therapeutic option for these patients [12, 27] . In a phase 1 study four of five patients died following complications after allo-SCT [12] . In Polish experience the results are much better. Eight patients proceeded to transplantation, two of them (25%) died due to complications related to allo-SCT, but six are still alive (75%), with no chance for survival in the pre-nivolumab era. Nivolumab demonstrated an accaptable safety profile in clinical trials and in real-life. We did not qualify to nivolumab therapy patients with a diagnosis of active autoimmune diseases, receiving systemic full dose corticosteroids or immunosuppressive therapy due to the higher risk of autoimmune toxicities. In the analysis of 52 advanced melanoma patients with preexisting autoimmune disorders, treatment with nivolumab induces 30% autoimmune diseases with the majority of rheumatoid disorders [29] . Interestingly, the use of immunosupressive drugs resulted in lower response rates [29] .
The AEs rate in our analysis was favorable; reported events were menegable and acceptable. AEs were mainly grade 1-2, grade 3 AEs occured in 31% of patients and resolved after supporting treatment.
Grade 4-5 AEs were not reported.
The study has limitations, due to its retrospective character, limited number of patients and short follow-up period. Further evaluation of optimal length of treatment, possibility to continue treatment beyond progression until clinical benefit is maintained is needed.
In conclusion, the data from this retrospective analysis confirm the high efficacy and safety of nivolumab monotherapy in heavily 
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